Research Analysts Offer Predictions for Hologic Q2 Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Equities research analysts at William Blair lowered their Q2 2025 earnings per share (EPS) estimates for shares of Hologic in a research note issued to investors on Thursday, February 6th. William Blair analyst A. Brackmann now expects that the medical equipment provider will earn $1.00 per share for the quarter, down from their previous forecast of $1.07. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Hologic's current full-year earnings is $4.27 per share.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%.

Several other analysts have also weighed in on HOLX. Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Morgan Stanley dropped their price target on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. BNP Paribas upgraded Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Finally, Wolfe Research started coverage on shares of Hologic in a research note on Friday, December 13th. They issued a "peer perform" rating for the company. Ten research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Hologic presently has a consensus rating of "Moderate Buy" and a consensus price target of $85.77.

Hologic Trading Up 0.1 %

HOLX stock traded up $0.09 during midday trading on Monday, reaching $63.62. 1,940,048 shares of the company traded hands, compared to its average volume of 2,545,433. The firm has a market capitalization of $14.36 billion, a price-to-earnings ratio of 20.07, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic has a 52-week low of $63.39 and a 52-week high of $84.67. The business has a 50 day moving average of $71.28 and a 200-day moving average of $77.37. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49.

Hedge Funds Weigh In On Hologic

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wedmont Private Capital raised its holdings in shares of Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider's stock worth $361,000 after buying an additional 162 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its stake in Hologic by 257.7% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,826 shares of the medical equipment provider's stock valued at $230,000 after purchasing an additional 2,036 shares during the last quarter. First Affirmative Financial Network acquired a new position in shares of Hologic in the third quarter valued at about $242,000. Exchange Traded Concepts LLC raised its stake in shares of Hologic by 74.9% in the third quarter. Exchange Traded Concepts LLC now owns 19,649 shares of the medical equipment provider's stock worth $1,601,000 after purchasing an additional 8,416 shares during the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new stake in shares of Hologic during the third quarter worth about $372,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.